Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous.

abstract：:Preferentially expressed antigen in melanoma (PRAME) is the best characterized member of the PRAME family of leucine-rich repeat (LRR) proteins. Mammalian genomes contain multiple members of the PRAME family whereas in other vertebrate genomes only one PRAME-like LRR protein was identified. PRAME is a cancer/testis an...

journal_title：Current cancer drug targets

authors： Hermes N,Kewitz S,Staege MS

更新日期：2016-01-01 00:00:00

abstract：:Oncolytic viruses can selectively replicate in and lead to tumor cell lysis with minimal infection/replication potential in adjoining non-neoplastic tissue. Because of paramount safety concerns, first-generation oncolytic viruses were designed to be significantly attenuated in their lytic potential. Results from recen...

journal_title：Current cancer drug targets

authors： Hardcastle J,Kurozumi K,Chiocca EA,Kaur B

更新日期：2007-03-01 00:00:00

abstract：:Prevention is one of the most important and promising strategies to control cancer. Many dietary bioactive compounds, mostly phytochemicals, have been found to decrease the risk of carcinogenesis. Modulating the metabolism and disposition pathways of carcinogens represents one of the major mechanisms by which dietary ...

journal_title：Current cancer drug targets

authors： Yu S,Kong AN

更新日期：2007-08-01 00:00:00

abstract：:Pokemon gene has crucial but versatile functions in cell differentiation, proliferation and tumorigenesis. It is a master regulator of the ARF-HDM2-p53 and Rb-E2F pathways. The facts that the expression of Pokemon is essential for tumor formation and many kinds of tumors over-express the Pokemon gene make it an attrac...

journal_title：Current cancer drug targets

authors： Tian Z,Wang H,Jia Z,Shi J,Tang J,Mao L,Liu H,Deng Y,He Y,Ruan Z,Li J,Wu Y,Ni B

更新日期：2010-12-01 00:00:00

abstract：:Obesity is rapidly becoming a global phenomenon. This is more than a cosmetic issue as obesity is associated with several life-threatening diseases, including colon cancer. Insulin resistance and inflammation, underlying factors in obesity-related diseases, promote colonocyte proliferation and suppress programmed cell...

journal_title：Current cancer drug targets

authors： Vanamala J,Tarver CC,Murano PS

更新日期：2008-11-01 00:00:00

abstract：BACKGROUND AND AIM:Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patient...

journal_title：Current cancer drug targets

authors： Santini D,Schiavon G,Vincenzi B,Cass CE,Vasile E,Manazza AD,Catalano V,Baldi GG,Lai R,Rizzo S,Giacobino A,Chiusa L,Caraglia M,Russo A,Mackey J,Falcone A,Tonini G

更新日期：2011-01-01 00:00:00

abstract：:Membrane ion channels participate in cancerous processes such as proliferation, migration and invasion, which contribute to metastasis. Increasing evidence indicates that voltage-dependent K(+) (Kv) channels are involved in the proliferation of many types of cells, including tumor cells. Kv channels have generated imm...

journal_title：Current cancer drug targets

authors： Bielanska J,Hernández-Losa J,Pérez-Verdaguer M,Moline T,Somoza R,Ramón Y Cajal S,Condom E,Ferreres JC,Felipe A

更新日期：2009-12-01 00:00:00

abstract：:MicroRNAs (miRNAs) are small non-coding RNAs that bind to the 3'untranslated region of target mRNAs and lead to translation repression or mRNA degradation, thus regulating important cell processes. MiRNA deregulation has been identified in virtually all types of cancer, and miRNA profiling has proved useful in cancer ...

journal_title：Current cancer drug targets

authors： Lionetti M,Agnelli L,Lombardi L,Tassone P,Neri A

更新日期：2012-09-01 00:00:00

abstract：:Arsenic trioxide (As2O3) has been used in the clinic for the treatment of acute promyelocytic 1eukemia and some solid tumors. However, its effectiveness against lung cancer has not been well demonstrated, and the underlying mechanism(s) of action remain unclear. In the present study, we found that As2O3 significantly ...

journal_title：Current cancer drug targets

authors： Yang MH,Zang YS,Huang H,Chen K,Li B,Sun GY,Zhao XW

更新日期：2014-01-01 00:00:00

abstract：:Castration-resistant prostate cancer remains incurable and a major cause of mortality worldwide. The absence of effective therapeutic approaches for advanced prostate cancer has led to an intensive search for novel treatments. Emerging nanomedical approaches have shown promising results, in vitro and in vivo, in impro...

journal_title：Current cancer drug targets

authors： Katsogiannou M,Peng L,Catapano CV,Rocchi P

更新日期：2011-10-01 00:00:00

abstract：:CXCR4 is a chemokine receptor implicated in the metastatic process. The CXCR4 ligand, CXCL12, was shown to bind also the CXCR7 receptor, a recently deorphanized chemokine receptor whose signalling pathway and function are still controversial. This study was conducted to determine patients clinic-pathological factors a...

journal_title：Current cancer drug targets

authors： D'Alterio C,Consales C,Polimeno M,Franco R,Cindolo L,Portella L,Cioffi M,Calemma R,Marra L,Claudio L,Perdonà S,Pignata S,Facchini G,Cartenì G,Longo N,Pucci L,Ottaiano A,Costantini S,Castello G,Scala S

更新日期：2010-11-01 00:00:00

abstract：:The greatest risk factor for the development of cervical and other cancers that have been linked to the human papillomavirus (HPV) family is the persistence of the virus. To persist for the decades required to develop HPV-related cancers, the virus must escape host immunity. HPV is a simple DNA virus that has evolved ...

journal_title：Current cancer drug targets

authors： Kanodia S,Fahey LM,Kast WM

更新日期：2007-02-01 00:00:00

abstract：:Human mesenchymal stem cells (hMSCs) consist of cells that can differentiate into mesenchymal tissues, including osteoblasts, adipocytes and chondrocytes. hMSCs constitute a particular stem cell niche in the stromal compartment of the bone marrow, and also play a role in maintaining the normal function of haematopoiet...

journal_title：Current cancer drug targets

authors： Cruet-Hennequart S,Prendergast AM,Barry FP,Carty MP

更新日期：2010-06-01 00:00:00

abstract：BACKGROUND:CYP1B1 is recognized as a valuable target for chemotherapy. It catalyzes the bioactivation of naphthoquinone oximes within certain cancer cell lines. However, the expression level of CYP1B1 in melanoma and the functional role regulating the activity of DMAKO-20 as a representative naphthoquinone oxime agains...

journal_title：Current cancer drug targets

authors： Cui J,Zhou X,Huang J,Cui J,Chen J

更新日期：2020-11-15 00:00:00

abstract：:Amplification of the HER-2 gene occurs in approximately 25% of breast cancers, causing up-regulation of key signaling pathways which control cell growth and survival. In breast cancer patients, HER-2 overexpression correlates with an aggressive phenotype and poor prognosis. HER-2, therefore, has become the focus of ma...

journal_title：Current cancer drug targets

authors： Browne BC,O'Brien N,Duffy MJ,Crown J,O'Donovan N

更新日期：2009-05-01 00:00:00

abstract：:Inactivation of the FHIT and TP53 genes is frequently observed in primary non-small cell lung cancers (NSCLC) and cell lines and may contribute to resistance to apoptotic stimuli elicited by various anti-tumor drugs. To evaluate a possible relationship between FHIT and TP53 status and response to platinum-analogue reg...

journal_title：Current cancer drug targets

authors： Cortinovis DL,Andriani F,Livio A,Fabbri A,Perrone F,Marcomini B,Pilotti S,Mariani L,Bidoli P,Bajetta E,Roz L,Sozzi G

更新日期：2008-08-01 00:00:00

abstract：:Cisplatin is one of the most commonly used drugs in the treatment of gastric cancer. However, drug resistance is a major obstacle for effective treatment and originates in multiple mechanisms such as enhanced DNA repair and anti-apoptosis. Our previous results demonstrated that XRCC1 was a key regulator of cisplatin i...

journal_title：Current cancer drug targets

authors： Ni P,Xu W,Zhang Y,Chen Q,Li A,Wang S,Xu S,Zhou J

更新日期：2015-01-01 00:00:00

abstract：:There is an emerging paradigm shift in oncology that seeks to emphasize molecularly targeted approaches for cancer prevention and therapy. Chalcones (1,3-diphenyl-2-propen-1-ones), naturally-occurring compounds with widespread distribution in spices, tea, beer, fruits and vegetables, consist of open-chain flavonoids i...

journal_title：Current cancer drug targets

authors： Jandial DD,Blair CA,Zhang S,Krill LS,Zhang YB,Zi X

更新日期：2014-01-01 00:00:00

abstract：:Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of hematopoietic progenitors manifest by cytopenias, bleeding, infection, and potential for progression to acute myelogenous leukemia. The wide spectrum of clinical manifestations, including variability in illness severity and potential for ...

journal_title：Current cancer drug targets

authors： Warlick ED,Smith BD

更新日期：2007-09-01 00:00:00

abstract：:The integrin family of cell surface receptors integrates cell-extracellular matrix interactions with the cell cytoskeleton and signalling across the cell membrane, resulting in an important role in cell adhesion, mobility and migration, proliferation, and survival. Changes in the number and identity of integrin recept...

journal_title：Current cancer drug targets

authors： Sheldrake HM,Patterson LH

更新日期：2009-06-01 00:00:00

abstract：BACKGROUND:Oncolytic viruses (OVs), which preferentially infect cancer cells and induce host anti-tumor immune responses, have emerged as an effective melanoma therapy. Tanapoxvirus (TANV), which possesses a large genome and causes mild self-limiting disease in humans, is potentially an ideal OV candidate. Interleukin-...

journal_title：Current cancer drug targets

authors： Zhang T,Kordish DH,Suryawanshi YR,Eversole RR,Kohler S,Mackenzie CD,Essani K

更新日期：2018-01-01 00:00:00

abstract：:Cancer drug therapy is undergoing a major transition from the previous pregenomic cytotoxic era to the new postgenomic era. Future mechanism-based therapeutic agents will increasingly be designed to act on molecular targets that are causally involved in the malignant progression of human cancers. Such agents are predi...

journal_title：Current cancer drug targets

authors： Workman P

更新日期：2001-05-01 00:00:00

abstract：:Lipophilic derivatives of the anticancer drug paclitaxel (PTX) were prepared by means of its conjugation to lipoamino acid (LAA) residues, with the aim of increasing drug accumulation in tumor cells. PTX was linked to the methyl esters of norleucine (C6) or 2-aminodecanoic acid (C10). A succinic acid group was used as...

journal_title：Current cancer drug targets

authors： Pignatello R,Paolino D,Pantò V,Pistară V,Calvagno MG,Russo D,Puglisi G,Fresta M

更新日期：2009-03-01 00:00:00

abstract：:The ubiquitin system controls protein stability and function. F-box proteins form SCF (SKP1-Cullin1-F-box protein)-type ubiquitin (E3) ligases to selectively target their substrates for degradation via the ubiquitin-proteasome pathway. Here, we review F-box proteins associated with cancer development. S-phase kinase-a...

journal_title：Current cancer drug targets

authors： Kitagawa K,Kitagawa M

更新日期：2016-01-01 00:00:00

abstract：:Recent publications on the molecular characterization of malignant glioma have had profound impact on the appreciation of tumoral heterogeneity within and between patients. Both these phenomena are implicated in the variability in clinical outcome between patients, as well as the inevitable recurrence of these tumors ...

journal_title：Current cancer drug targets

authors： Balvers RK,Dirven CM,Leenstra S,Lamfers ML

更新日期：2017-01-01 00:00:00

abstract：:Several subtypes of T cells are located in a tumor environment, each of which supplies their energy using different metabolic mechanisms. Since the cancer cells require high levels of glucose, the conditions of food poverty in the tumor environment can cause inactivation of immune cells, especially the T-effector cell...

journal_title：Current cancer drug targets

authors： Iranparast S,Tayebi S,Ahmadpour F,Yousefi B

更新日期：2020-01-01 00:00:00

abstract：:Tumor heterogeneity within various cancer types including breast carcinoma is pivotal in the manifestations of tumor hallmarks. Tumor heterogeneity is seen as a common landscape where intra-tumoral components including cellular and non-cellular factors create an interface with outside environment that leads to the uni...

journal_title：Current cancer drug targets

authors： Tandon I,Sharma NK

更新日期：2019-01-01 00:00:00

abstract：:Despite advances in multidisciplinary approaches, the prognosis for most patients with malignant gliomas is poor. Malignant gliomas are highly vascularized tumors with elevated expression of vascular endothelial growth factor (VEGF), an important mediator of angiogenesis. Recent studies of bevacizumab, an anti-VEGF mo...

journal_title：Current cancer drug targets

authors： Soffietti R,Trevisan E,Bertero L,Bosa C,Ruda R

更新日期：2012-03-01 00:00:00

abstract：:The capacity to induce new blood vessel formation or to repair damaged vessels is an attractive idea that has, for a long time, captured the attention and imagination of researchers. Beside the identification of the pro-angiogenic growth factors and their counterpart inhibitors, the discovery of endothelial progenitor...

journal_title：Current cancer drug targets

authors： Pasquier E,Dias S

更新日期：2010-12-01 00:00:00

abstract：BACKGROUND:MicroRNA (miRNA) therapy, which was widely considered to treat a series of cancer, has been confronted with numerous obstacles to being delivered into target cells because of its easy biodegradation and instability. METHODS:In this research, we successfully constructed 11-mercaptoundecanoic acid modified go...

journal_title：Current cancer drug targets

authors： Yan LJ,Guo XH,Wang WP,Hu YR,Duan SF,Liu Y,Sun Z,Huang SN,Li HL

更新日期：2019-01-01 00:00:00